416 results on '"Fey, Martin F"'
Search Results
2. Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials.
3. The Leukemic Fusion Gene AML1-MDS1-EVI1 Suppresses CEBPA in Acute Myeloid Leukemia by Activation of Calreticulin
4. The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation
5. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
6. Induction of the autophagy-associated gene MAP1S via PU.1 supports APL differentiation
7. Leukaemia and Pregnancy
8. PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells
9. Deregulated expression of Kruppel-like factors in acute myeloid leukemia
10. Principles of systemic therapy
11. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
12. Single early palliative care intervention added to usual oncology care for patients with advanced cancer: A randomized controlled trial (SENS Trial)
13. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
14. Long-Term Followup Results of 1 Cycle of Adjuvant Bleomycin, Etoposide and Cisplatin Chemotherapy for High Risk Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis
15. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
16. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
17. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
18. The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients
19. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression
20. What is the current treatment of PTLD after liver transplantation?
21. MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma
22. Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells
23. Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia
24. CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation
25. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
26. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2
27. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
28. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)
29. Mortality in cancer patients receiving recombinant human erythropoiesis-stimulating agents: Individual patient data meta-analysis based on randomized trials
30. SIRT1 is downregulated during neutrophil differentiation of acute promyelocytic leukaemia cells
31. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation
32. Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
33. Prognostic Value of Extracapsular Tumor Spread for Locoregional Control in Premenopausal Patients With Node-Positive Breast Cancer Treated With Classical Cyclophosphamide, Methotrexate, and Fluorouracil: Long-Term Observations From International Breast Cancer Study Group Trial VI
34. Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience
35. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)
36. Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV
37. Assessment of Differences in Patient Populations Selected for or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials
38. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL)
39. Distinct patterns of p73 expression in B-CLL (B-cell chronic lymphocytic leukaemia) as compared to normal B-lymphocytes.
40. Ovarian cancer: An institutional review of patterns of care and prognosis.
41. Introduction
42. Clonal Loss of Heterozygosity in Microdissected Hodgkin and Reed-Sternberg Cells
43. BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation
44. SAMPLING BIAS AND LOGISTICAL PROBLEMS OF MOLECULAR ANALYSES IN A CLINICAL LEUKAEMIA TRIAL
45. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
46. A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)
47. Impact of the Human Genome Project on the clinical management of sporadic cancers
48. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias
49. Detection of microsatellite markers in leukaemia using DNA from archival bone marrow smears
50. LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.